Can lisdexamfetamine (Vyvanse) be taken concomitantly with psilocybin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Vyvanse and Psilocybin: Concomitant Use

Do not combine Vyvanse (lisdexamfetamine) with psilocybin mushrooms due to serious risk of hypertensive emergency, particularly life-threatening cardiovascular events including myocardial infarction. While synthetic psilocybin alone may theoretically be safer, the combination with amphetamines creates unacceptable cardiovascular and psychiatric risks.

Critical Safety Concerns

Hypertensive Emergency Risk

The FDA labeling for Vyvanse explicitly warns about serotonin syndrome when amphetamines are combined with serotonergic drugs 1. Psilocybin acts as a potent serotonin 5-HT2A receptor agonist, placing it squarely in this high-risk category. The warning specifically mentions that serotonin syndrome can manifest as:

  • Mental status changes (agitation, hallucinations, delirium, coma)
  • Autonomic instability (tachycardia, labile blood pressure, hyperthermia)
  • Neuromuscular symptoms (tremor, rigidity, myoclonus)
  • Seizures

Case Report Evidence

A 2024 case report documents a hypertensive emergency with ST-elevation myocardial infarction in a 42-year-old taking extended-release dextroamphetamine-amphetamine (similar mechanism to Vyvanse) combined with psilocybin mushrooms 2. The patient developed:

  • Severe hypertension with chest pain
  • Palpitations and headache
  • ST-elevation on ECG
  • Required emergency cardiac catheterization

Critical distinction: The authors suspect phenylethylamine compounds in Psilocybe cubensis mushrooms (not pure psilocybin) interacted with the amphetamine to produce this emergency 2. This suggests psilocybin mushrooms carry additional risk beyond synthetic psilocybin alone.

Mechanism of Interaction

Vyvanse (lisdexamfetamine) is a prodrug that converts to dextroamphetamine, which:

  • Increases norepinephrine and dopamine release
  • Has indirect serotonergic effects
  • Increases cardiovascular stimulation (blood pressure, heart rate)

When combined with psilocybin's serotonergic activity, this creates:

  • Additive cardiovascular stimulation
  • Risk of serotonin syndrome
  • Potential for severe hypertension
  • Enhanced psychiatric adverse effects (psychosis, mania, agitation)

Additional FDA Warnings Relevant to This Combination

The Vyvanse label warns about psychiatric adverse reactions, noting that amphetamines can cause new psychotic or manic symptoms in 0.1% of patients even without prior psychiatric history 1. Psilocybin inherently produces altered consciousness and perceptual changes 3. The combination amplifies risk of:

  • Severe anxiety or panic
  • Psychotic symptoms
  • Agitation requiring emergency intervention
  • Unpredictable psychological reactions

Clinical Recommendations

If Patient Has Already Combined These Drugs:

  1. Immediate assessment for signs of serotonin syndrome or hypertensive emergency
  2. Monitor vital signs closely (blood pressure, heart rate, temperature)
  3. Assess for chest pain, severe headache, altered mental status
  4. Low threshold for emergency department evaluation if any concerning symptoms
  5. Supportive care and benzodiazepines (lorazepam) if needed for agitation

For Patients Considering Psilocybin Therapy:

  1. Discontinue Vyvanse at least 24-48 hours before psilocybin administration (based on Vyvanse's ~10-12 hour half-life, allowing 2-3 half-lives for clearance)
  2. Coordinate with prescribing physician regarding ADHD symptom management during washout period
  3. If psilocybin is being used in research/therapeutic context, most clinical trials explicitly exclude patients on stimulants 4
  4. Consider alternative ADHD management strategies during psilocybin treatment period

Important Caveats:

  • The systematic review on drug interactions notes limited data on psychostimulant-psilocybin combinations 4
  • Most psilocybin clinical trials require discontinuation of psychiatric medications before enrollment to isolate effects and minimize risk 5
  • One case report showed serotoninergic antidepressants could be continued with psilocybin 5, but this does NOT apply to stimulants, which have different mechanisms and cardiovascular effects
  • Psilocybin mushrooms contain additional compounds (like phenylethylamine) beyond pure psilocybin that may increase interaction risk 2

Bottom Line

The combination poses unacceptable risk of life-threatening cardiovascular events and severe psychiatric reactions. The single documented case of hypertensive emergency with myocardial infarction 2, combined with FDA warnings about serotonin syndrome 1, makes this combination contraindicated in clinical practice. If psilocybin therapy is medically indicated, Vyvanse must be discontinued with appropriate washout period under physician supervision.

References

Related Questions

When is it appropriate to restart Adderall (mixed‑amphetamine salts) following psilocybin ingestion?
Can a generally healthy adult without hypertension, seizure disorder, substance misuse, or MAOI use safely combine bupropion (Wellbutrin) with Adderall (amphetamine/dextroamphetamine)?
Is it safe to combine psilocybin with methylphenidate (a stimulant)?
What is the recommended waiting period after the last dose of Suboxone (buprenorphine and naloxone) before switching to oral oxycodone for a patient with inadequate chronic pain control?
Are there interactions between bupropion (Wellbutrin) and MDMA (Molly)?
What are the appropriate needle gauge and length for intramuscular injections in adults (including obese adults), children (10–30 kg and 30–50 kg), and infants (<10 kg) for deltoid and gluteal sites?
For a patient with a urine culture positive for Escherichia coli who is currently on ciprofloxacin, should therapy be continued, and what is the appropriate dosing and alternative options if the isolate is resistant?
What is the appropriate treatment for a patient with a positive PCR (qualitative DNA) for Ehrlichia chaffeensis?
What class of medication is finasteride?
Is nystatin the same as miconazole for treating a moist erythematous intertriginous rash under the left breast of a 75‑year‑old woman refractory to topical corticosteroids?
Can a 14‑year‑old safely take vitamin D (cholecalciferol) 50,000 IU weekly?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.